Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers classification and therapeutic decision-making for malignant gliomas.

Current treatment options in oncology - 1 Dec 2012

Olar Adriana, Aldape Kenneth D

Abstract excerpt

OPINION STATEMENT: Diffuse gliomas are the most common primary brain tumors, with glioblastoma (GBM) encompassing more than 50 % of all cases. Despite aggressive therapy, patients nearly always succumb to their disease and the survival for patients with GBM is approximately 1 year. During past years, numerous scientific contributions have reshaped the field of neuro-oncology and neuropathology. A series of...

Topics

Biomarkers, Tumor
Brain Neoplasms
CpG Islands
DNA Modification Methylases
DNA Repair Enzymes
Decision Making
ErbB Receptors
Gene Expression Regulation, Neoplastic
Glioma
Humans
Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mutation

Prognosis

Proto-Oncogene Proteins B-raf

Tumor Suppressor Protein p53

Tumor Suppressor Proteins

Source

Identifiers

PMID: 22956341
DOI: 10.1007/s11864-012-0210-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers classification and therapeutic decision-making for malignant gliomas.PMID 22956341Read ↗

Molecular pathology and clinical implications of diffuse glioma.Semantic proximity Read ↗

Opinion & Special Article: Glioma Classification: How to Interpret Molecular Markers in a Diffuse Glioma Pathology Report.Semantic proximity Read ↗

The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 1-Key Points of the Fifth Edition and Summary of Imaging Findings on Adult-Type Diffuse Gliomas.Semantic proximity Read ↗

The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 2-Summary of Imaging Findings on Pediatric-Type Diffuse High-Grade Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Circumscribed Astrocytic Gliomas.Semantic proximity Read ↗

Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update.Semantic proximity Read ↗

Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics.Semantic proximity Read ↗

The Role of Molecular Diagnostics in the Management of Patients with Gliomas.Semantic proximity Read ↗

Diffuse gliomas to date and beyond 2016 WHO Classification of Tumours of the Central Nervous System.Semantic proximity Read ↗

Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse GliomasSemantic proximity Read ↗

Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and TherapySemantic proximity Read ↗

Glioblastoma: An Update in Pathology, Molecular Mechanisms and BiomarkersSemantic proximity Read ↗

Adult-type Diffuse Gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.